更年期のほてりの世界市場- 2023-2030

市場概要

更年期のほてりの世界市場規模は、2022年に米国で135億米ドルに達し、2030年には205億米ドルに達することで有利な成長が予測されます。更年期のほてり症の世界市場は、2023年から2030年の予測期間中に5.5%のCAGRを記録しています。

更年期のほてり市場は、更年期のほてりの有病率の増加、更年期のほてりの発生率の増加、高齢化社会の進展、更年期とそれに伴う症状に対する認識と理解の向上、女性の健康に対する関心の高まり、治療オプションの進歩、ライフスタイルや好みの変化といった要因によって牽引されています。

更年期のほてり市場には、治療効果の限界、更年期のほてり治療薬の副作用、治療費の高さなど、多くの市場抑制要因が存在します。

市場力学

更年期のほてりの有病率の増加

更年期のほてりの有病率の増加は、予測期間中の市場シェアを押し上げる主要因となっています。更年期のほてりの有病率は、女性の高齢化、平均寿命の延長、喫煙、飲酒、ジャンクフードなどのライフスタイルの変化、ホルモンの変化、認知度や治療の必要性、このライフステージにおける女性の効果的な管理オプションやサポートの必要性などにより増加しています。

ホットフラッシュの有病率は個人差があり、ある人は他の人よりも頻繁に、また激しく経験することがあります。ヘルスケアプロバイダーと製薬会社は、ほてりの影響を緩和し、この一般的な更年期症状を経験する女性の生活の質を高めるために、治療法の開発および改善に継続的に取り組んでいます。

更年期のほてり治療薬の副作用について

更年期のほてり治療薬の副作用は、市場シェアを阻害する大きな要因となっています。ホルモン剤と非ホルモン剤を含む更年期のほてり治療薬には、潜在的な副作用がある可能性があります。すべての人がこれらの副作用を経験するわけではなく、副作用の重症度や頻度も様々であることに留意する必要があります。

COVID-19の影響分析

COVID-19の流行は、更年期のほてりの管理や治療を含む、ヘルスケアの様々な側面に大きな影響を与えました。パンデミックの間、ヘルスケアシステムは、病院の過密状態、スタッフ不足、COVID-19対応にリソースを振り向ける必要性など、大きな課題に直面しました。更年期症状の管理に関連するものを含め、緊急でないヘルスケアや選択的なヘルスケアへの受診は、場合によっては延期または中止され、診断や治療の遅れにつながっています。

COVID-19のパンデミックは、世界中の個人に大きな心理的影響を与えました。パンデミックに起因するストレス、不安、感情的な障害は、更年期のほてりを含む症状を悪化させる可能性があります。女性は、パンデミックによる更年期症状への心理的・感情的影響を管理するために、さらなるサポートとリソースを必要とするかもしれません。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争は、同地域の更年期のほてり市場に影響を及ぼしました。紛争は、影響を受けた地域のヘルスケア・インフラに負担をかける可能性があります。ヘルスケアサービスの中断、医療施設の損傷、医療従事者の移動は、更年期症状管理を含むヘルスケアの利用可能性とアクセシビリティに影響を与える可能性があります。

紛争は、直接的・間接的に、ストレスや戦争中の混乱した環境などにより、更年期のほてり市場に影響を与えます。これは、更年期のほてりの診断と治療を含む、女性のヘルスケアサービスへのアクセスを妨げる可能性があります。

目次

第1章 調査手法と範囲

• 調査手法
• 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 更年期のほてりの増加
  • 抑制要因
    • 更年期のほてり治療薬の副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 法規制の分析

第6章 COVID-19の分析

第7章 製品別

• ホルモン製品
  • エストロゲン
    • プレマリン
    • ビベール
    • ビベルドット
  • プロゲステロン
    • プロメトリアム
  • 配合製品
    • プレプロ
    • デュアベ
• 非ホルモン製品
  • ブリスデル
  • その他
• その他

第8章 流通チャネル別

• オンラインストア
• 小売店
• その他

第9章 エンドユーザー別

• 病院
• 専門医院
• 学術・研究機関

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A（合併・買収）分析

第12章 企業プロファイル

• Bayer AG
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展状況
• Novartis AG
• Pfizer Inc.
• Novo Nordisk Corporation
• AbbVie Inc.（Allergan Plc）
• Hisamitsu Pharmaceutical Co. Inc.
• Ferring Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Noven Pharmaceuticals
• AstraZeneca

第13章 付録

Market Overview

The Global Menopausal Hot Flashes Market size reached US$ 13.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 20.5 billion by 2030. The Global Menopausal Hot Flashes Market is exhibiting at a CAGR of 5.5% during the forecast period 2023-2030.

The menopausal hot flashes market is driven by factors such as an increasing prevalence of menopausal hot flashes, growing incidence of menopausal hot flashes, a growing aging population, increasing awareness and understanding of menopause and its associated symptoms, increasing focus on women's health, advancements in treatment options, and changing lifestyles and preferences.

There are many restraints and challenges associated with the menopausal hot flashes market, including limited treatment efficacy, side effects of menopausal hot flashes drugs, high cost of the treatment, and so on.

Market Dynamics

Increasing Prevalence of Menopausal Hot Flashes

The increasing prevalence of menopausal hot flashes is a major factor driving the market share during the forecast period. The prevalence of menopausal hot flashes is increasing due to the aging women population, longer life expectancy, lifestyle changes like smoking, alcohol consumption, and junk food, hormonal changes, awareness and seeking treatment, and the need for effective management options and support for women during this stage of life.

The prevalence of hot flashes can vary among individuals, with some experiencing them more frequently and intensely than others. Healthcare providers and pharmaceutical companies are continuously working to develop and improve treatment options to alleviate the impact of hot flashes and enhance the quality of life for women experiencing this common menopausal symptom.

Side Effects of Menopausal Hot Flashes Drugs

The side effects associated with menopausal hot flashes drugs are a major factor hindering the market share. Menopausal hot flashes drugs, including hormonal and non-hormonal medications, can have potential side effects. It is important to note that not all individuals will experience these side effects, and the severity and frequency of side effects can vary.

COVID-19 Impact Analysis

The COVID-19 pandemic has significantly impacted various aspects of healthcare, including the management and treatment of menopausal hot flashes. During the pandemic, healthcare systems have faced significant challenges, including overwhelmed hospitals, staff shortages, and the need to redirect resources to the COVID-19 response. Non-urgent and elective healthcare visits, including those related to menopausal symptom management, have been postponed or canceled in some cases, leading to delays in diagnosis and treatment.

The COVID-19 pandemic has had a significant psychological impact on individuals worldwide. Stress, anxiety, and emotional disturbances resulting from the pandemic can exacerbate menopausal symptoms, including hot flashes. Women may require additional support and resources to manage the psychological and emotional effects of the pandemic on their menopausal symptoms.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict impacted the menopausal hot flashes market in the region. The conflict can strain the healthcare infrastructure in the affected regions. Disruptions in healthcare services, damaged medical facilities, and displacement of healthcare professionals can affect the availability and accessibility of healthcare, including menopausal symptom management.

The conflict, directly and indirectly, affected the menopausal hot flashes market due to the stress, disruptive environment during the war, and so on. This may hamper the women's access to healthcare services, including diagnosis and treatment of menopausal hot flashes.

Segment Analysis

The Global Menopausal Hot Flashes Market is segmented based on product, distribution channel, end-user, and region.

Hormonal Products are Expected to Dominate the Market Share

hormonal products are expected to dominate the market share, accounting for 47.2% during the forecast period. Hormonal products, such as estrogen therapy, progesterone therapy, or combined estrogen-progestin therapy, have been widely used for many years to manage menopausal symptoms, including hot flashes. These products work by supplementing the declining estrogen levels in the body during menopause, which can help alleviate hot flashes and other associated symptoms.

Hormonal products are often considered the most effective treatment option for menopausal hot flashes, providing significant relief for many women. They are available in various formulations, including oral tablets, patches, creams, gels, and vaginal rings, offering flexibility based on individual needs.

Geographical Analysis

North America Holds the Largest Market Share during the forecast period

North America holds the largest market share of 41.5% during the forecast period due to rising demand for menopausal hot flashes treatment. North America, which includes the United States and Canada, has a significant population of women in the menopausal age range, contributing to the demand for effective management of menopausal symptoms, including hot flashes.

Competitive Landscape

The major global players in the market include: Bayer AG, Novartis AG, Pfizer Inc, Novo Nordisk Corporation, AbbVie Inc. (Allergan Plc), Hisamitsu Pharmaceutical Co. Inc., Ferring Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Noven Pharmaceuticals, and AstraZeneca.

Why Purchase the Report?

• To visualize the Global Menopausal Hot Flashes Market segmentation based on product, distribution channel, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of menopausal hot flashes market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Menopausal Hot Flashes Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Distribution Channel
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of menopausal hot flashes
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects of menopausal hot flashes drugs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Post COVID-19 & Future Scenario
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Product

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.1.2. Market Attractiveness Index, By Product
• 7.2. Hormonal Products*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Estrogen
    • 7.2.3.1. Premarin
    • 7.2.3.2. Vivelle
    • 7.2.3.3. Vivelle-Dot
  • 7.2.4. Progesterone
    • 7.2.4.1. Prometrium
  • 7.2.5. Combination Products
    • 7.2.5.1. Prempro
    • 7.2.5.2. Duavee
• 7.3. Non-Hormonal Products
  • 7.3.1.1. Brisdelle
  • 7.3.1.2. Others
• 7.4. Others

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Online Stores*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail outlets
• 8.4. Others

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Specialty Clinics
• 9.4. Academic & Research Institutes

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Bayer AG*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Novartis AG
• 12.3. Pfizer Inc.
• 12.4. Novo Nordisk Corporation
• 12.5. AbbVie Inc. (Allergan Plc)
• 12.6. Hisamitsu Pharmaceutical Co. Inc.
• 12.7. Ferring Pharmaceuticals
• 12.8. Teva Pharmaceutical Industries Ltd.
• 12.9. Noven Pharmaceuticals
• 12.10. AstraZeneca

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us